Anavex Life Sciences Corp (AVXL)

[B60611]

Things could move significantly just on anticipation, as it did for companies like Axovant and Neurotrope prior to their failed readouts. It'll be a lot harder to contain the stock when intermediate results could be released at any time, and even if investors knew for a fact we wouldn't get them until a set date, the stock isn't going to go from where it is now to where it will be ($50+++) with confirmatory results. A risk / reward analysis will be performed sometime after the patients have been dosed, and the stock will move significantly prior to results. Where it could go from where it is now to $50 ($2.5B market cap) overnight is with a significant upfront cash payment partnership. $500 mill should do it. Heck, Axon reached a $3B market cap ($60 AVXL SP) on the strength of $200 mill in cash and a recycled drug....albeit, with more than a little help from their friends.